Liev Schreiber is heading back to Broadway this spring in a revival of "Glengarry Glen Ross," and the ticket situation has already turned into the most heated drama of the theater season.
Fans who waited for the general on-sale this week found themselves staring at a virtual queue that stretched past 40,000 people before the page even loaded properly.
The production, which also stars Kieran Culkin and Bob Odenkirk, is the kind of stacked cast that makes theater obsessives lose their minds.
But the pricing has become the real conversation.
Face-value seats climbed well past $400 in the orchestra, and resale listings appeared within minutes at triple that, prompting a wave of frustrated posts across social media.
Schreiber hasn't addressed the ticket frenzy directly, though he did tell a red carpet reporter this month that returning to the stage "feels like coming home after a long trip." The 57-year-old last appeared on Broadway in 2017, and his absence has clearly built up demand.
Theater message boards are now full of fans comparing strategies, from lottery entries to same-day rush lines.
What makes this particular scramble interesting is timing.
Culkin is fresh off an awards-season run that made him one of the most in-demand actors in Hollywood, and Odenkirk's post-"Better Call Saul" choices are being watched closely.
Putting all three on one stage turned a standard revival into a cultural event, whether the producers intended that or not.
The production also arrives during a broader reckoning over Broadway accessibility.
Several shows this season have experimented with capped pricing and digital lotteries, but the resale market keeps finding ways around those guardrails.
Industry watchers say the "Glengarry" situation could become a test case for how aggressively theaters police secondary sellers.
For Schreiber, the moment carries a different weight.
He's spent the past several years balancing prestige television, documentary work, and a public profile that's stayed remarkably low-key given his famous family ties.
A Broadway comeback with this much heat around it puts him squarely back in the spotlight, whether he wants the attention or not.
Previews begin in March, which means the real reviews, and the real debates about whether the show lives up to the casting, are still weeks away.
Until then, the loudest conversation isn't about Mamet's dialogue or the direction.
It's about who actually gets to sit in the room.
Our take: Broadway keeps insisting it wants new audiences, then prices them out before the first preview.
Schreiber is genuinely great on stage, and this cast deserves a full house, not a resale lottery.
Final Thoughts
If the industry wants theater to stay a living art form, it needs to fix the front door, not just the marquee.